Crystalline levosalbutamol sulphate (Form II)

摘要

The invention provides crystalline levosalbutamol sulphate polymorphic Form II. Form II is characterised by a powder XRD pattern with peaks at 8.7, 9.6, 15.2, 15.7, 19.1, 27.2, 30.7 ± 0.2 degrees 2 theta. Processes for making polymorphic Form II and pharmaceutical composition comprising it are provided. A preferred formulation comprises a pharmaceutical composition comprising crystalline levosalbutamol sulphate form II, a glucocorticoid and a pharmaceutically acceptable carrier.